清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Combining Anti-epidermal Growth Factor Receptor (EGFR) Therapy with Immunotherapy in Metastatic Colorectal Cancer (mCRC)

医学 西妥昔单抗 帕尼单抗 免疫疗法 结直肠癌 肿瘤科 联合疗法 内科学 靶向治疗 表皮生长因子受体 临床试验 癌症
作者
Feng Xiong,Yuwen Zhou,Ya-Ting Hao,Gui-Xia Wei,Xiaorong Chen,Meng Qiu
出处
期刊:Expert Review of Gastroenterology & Hepatology [Taylor & Francis]
卷期号:18 (4-5): 185-192 被引量:3
标识
DOI:10.1080/17474124.2023.2232718
摘要

ABSTRACTIntroduction Monoclonal antibodies binding the EGFR, such as cetuximab and panitumumab, have been extensively used as targeted therapy for the treatment of mCRC. However, in clinical practice, it has been found that these treatment options have some limitations and fail to fully exploit their immunoregulatory activities. Meanwhile, because of the limited effects of current treatments, immunotherapy is being widely studied for patients with mCRC. However, previous immunotherapy trials in mCRC patients have had unsatisfactory outcomes as monotherapy. Thus, combinatorial treatment strategies are being researched.Areas covered The authors retrieved relevant documents of combination therapy for mCRC from PubMed and Medline. This review elaborates on the knowledge of immunomodulatory effects of anti-EGFR therapy alone and in combination with immunotherapy for mCRC.Expert opinion Although current treatment options have improved median overall survival (OS) for advanced disease to 30 months, the prognosis remains challenging for those with metastatic disease. More recently, the combination of anti-EGFR therapy with immunotherapy has been shown activity with complementary mechanisms. Hence, anti-EGFR therapy in combination with immunotherapy may hold the key to improving the therapeutic effect of refractory mCRC.KEYWORDS: Anti-EGFR therapycombination therapyimmune checkpoint inhibitorsimmunomodulationmetastatic colorectal cancer Article highlights Despite significant improvements in colorectal cancer (CRC) treatment, the prognosis of patients with mCRC is still poor, with a median overall survival (OS) of approximately 30 months. Although anti-EGFR therapy and immunotherapy are currently seen as confirmed treatment options for patients with mCRC, both are associated with limited efficacy by fueling primary and acquired resistance. Therefore, there is great interest in developing of combined treatment strategies that can enhance efficacy by overcoming the limitations of targeted and immune-based therapies.Anti-epidermal Growth Factor Receptor (Anti-EGFR) therapy and immunotherapy complement each other, by fully and synergistically stimulating both innate and adaptive immune systems against cancer cells, which provides the rationale for combination therapy.Various combinations have been investigated in clinical studies, including Anti-EGFR mAbs plus ICIs; Anti-EGFR mAbs, ICIs plus chemotherapy; BRAF inhibitors, Anti-EGFR mAbs plus ICIs.Some clinical trials are associated with improved survival and tolerated toxicities in treating patients with mCRC, which indicates that anti-EGFR therapy in combination with immunotherapy may hold the key to improving the therapeutic effect of refractory mCRC.The possibilities of anti-EGFR therapy in combination with immunotherapy should be further explored in the future.Declaration of interestThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Reviewer disclosuresPeer reviewers on this manuscript have no relevant financial or other relationships to disclose.Author ContributionsFeng Xiong collected data, reviewed the literature and wrote the manuscript. Yu-wen Zhou rechecked the manuscript and assisted in drawing. Ya-Ting Hao, Gui-Xia Wei and Xiao-Rong Chen contributed to the proofreading and revision of the manuscript. Meng Qiu designed and revised the manuscript. All authors contributed to the review and approved the submitted version.Additional informationFundingThis paper was funded by the Sichuan Science and Technology Department Key Research and Development Project (grant no. 2022YFS0209) and 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (grant no. ZYJC21017).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CHENG发布了新的文献求助30
4秒前
呆萌的鞯完成签到,获得积分10
7秒前
清脆乘云完成签到,获得积分10
10秒前
12秒前
KalEl发布了新的文献求助10
12秒前
沉默怡完成签到,获得积分10
27秒前
MassTestA1发布了新的文献求助50
32秒前
畅快天空完成签到,获得积分10
50秒前
zhaoty完成签到,获得积分10
51秒前
90min完成签到 ,获得积分10
54秒前
森莫莓完成签到,获得积分10
1分钟前
成就苞络完成签到,获得积分10
1分钟前
如意嫣完成签到,获得积分10
1分钟前
Gone完成签到,获得积分10
1分钟前
外向的以莲完成签到,获得积分10
1分钟前
MassTestA1的应助被MassTestA1采纳,获得30
1分钟前
MassTestA1对应助文件撤销了驳回
1分钟前
谦让康完成签到 ,获得积分10
1分钟前
隐形的芷文完成签到,获得积分10
1分钟前
动听的谷波完成签到,获得积分10
1分钟前
外向如雪完成签到,获得积分10
1分钟前
1分钟前
syvshc的应助被科研通管家采纳,获得10
1分钟前
洁净代云发布了新的文献求助10
1分钟前
发嗲的服饰完成签到,获得积分10
2分钟前
2分钟前
KalEl发布了新的文献求助10
2分钟前
酷酷乐双完成签到,获得积分10
2分钟前
闪闪青雪完成签到,获得积分10
2分钟前
2分钟前
共享精神的应助被洁净代云采纳,获得10
2分钟前
mochalv123发布了新的文献求助10
2分钟前
苗苗完成签到,获得积分10
2分钟前
linj完成签到,获得积分10
3分钟前
风信子完成签到,获得积分10
3分钟前
17991完成签到,获得积分10
3分钟前
瘦瘦的如冰完成签到,获得积分10
3分钟前
berry完成签到,获得积分10
3分钟前
Jasonkun完成签到,获得积分10
3分钟前
冷傲的月饼完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185453
求助须知:如何正确求助?哪些是违规求助? 9574168
关于积分的说明 21834462
捐赠科研通 7783010
什么是DOI,文献DOI怎么找? 3434570
关于科研通互助平台的介绍 2558900
邀请新用户注册赠送积分活动 2481326